Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.
Barat A, Smeets D, Moran B, Zhang W, Cao S, Das S, Klinger R, Betge J, Murphy V, Bacon O, Kay EW, Van Grieken NCT, Verheul HMW, Gaiser T, Schulte N, Ebert MP, Fender B, Hennessy BT, McNamara DA, O'Connor D, Gallagher WM, Cremolini C, Loupakis F, Parikh A, Mancao C, Ylstra B, Lambrechts D, Lenz HJ, Byrne AT, Prehn JHM. Barat A, et al. Among authors: klinger r. Sci Rep. 2020 Jun 17;10(1):9778. doi: 10.1038/s41598-020-65869-2. Sci Rep. 2020. PMID: 32555399 Free PMC article.
Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Zuurbier L, et al. Among authors: klinger r. Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306. Oncotarget. 2017. PMID: 28487489 Free PMC article.
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B. van Dijk E, et al. Among authors: klinger r. J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24. J Clin Oncol. 2018. PMID: 29792754 Clinical Trial.
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.
Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT. Smeets D, et al. Among authors: klinger r. Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6. Nat Commun. 2018. PMID: 30291241 Free PMC article.
Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.
Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, Bacon O, Kay E, Hennessy B, Murphy V, Ylstra B, Lambrechts D, Byrne AT, Gallagher WM, O'Connor DP. Moran B, et al. Among authors: klinger r. Oncotarget. 2017 Jul 18;8(29):48126-48137. doi: 10.18632/oncotarget.18296. Oncotarget. 2017. PMID: 28611295 Free PMC article.
microRNAs: a new class of breast cancer biomarkers.
Mulrane L, Klinger R, McGee SF, Gallagher WM, O'Connor DP. Mulrane L, et al. Among authors: klinger r. Expert Rev Mol Diagn. 2014 Apr;14(3):347-63. doi: 10.1586/14737159.2014.901153. Expert Rev Mol Diagn. 2014. PMID: 24649821 Review.
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM, Russell NM, Barron S, Wang CA, Loughman T, Dynoodt P, Fender B, Lopez-Ruiz C, O'Grady A, Sheehan KM, Fay J, Amberger-Murphy V, Saha A, Klinger R, Gonzalez CA, Al-Attar N, Rahman A, O'Leary D, Lanigan FT, Bracken AP, Crown J, Kelly CM, O'Connor DP, Gallagher WM. Lynch SM, et al. Among authors: klinger r. Eur J Cancer. 2021 Jul;152:78-89. doi: 10.1016/j.ejca.2021.04.016. Epub 2021 Jun 2. Eur J Cancer. 2021. PMID: 34090143 Free article.
Vitamin D receptor as a target for breast cancer therapy.
Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ. Murray A, et al. Among authors: klinger r. Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17. Endocr Relat Cancer. 2017. PMID: 28213567
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM. Li B, et al. Among authors: klinger r. Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28. Cancer Res. 2017. PMID: 28455421
254 results